Emoxy-optic drops 1%, 5 ml

• hemorrhage in the anterior chamber of the eye (treatment);

• hemorrhages in the sclera in the elderly (treatment and prevention);

• inflammation and burns of the cornea (treatment and prevention);

• complications of myopia (treatment);

• corneal protection (when wearing contact lenses)

Emoxy-opticЃ is prescribed for adults. Instilled into the conjunctival sac, 1-2 drops 2-3 times / day.

The course of treatment is 3-30 days. If necessary and well tolerated, the course of treatment can be continued up to 6 months and can be repeated 2-3 times a year.

Eye drops 1% are colorless or slightly colored, slightly opalescent.

methylethylpyridinol hydrochloride (emoxipin) 10 mg

Excipients : sodium sulfite anhydrous, sodium benzoate, potassium dihydrogen phosphate (potassium phosphate monobasic), sodium hydrogen phosphate dodecahydrate (sodium phosphate disubstituted 12-aqueous), methylcellulose, water d / i.

• pregnancy;

• lactation period (breastfeeding);

• children and adolescents up to 18 years old;

• hypersensitivity to the components of the drug.

pharmachologic effect

An antioxidant drug that prevents lipid peroxidation of cell membranes. It has angioprotective, antiplatelet and antihypoxic activity.

Reduces capillary permeability and strengthens the vascular wall (angioprotective effect). Reduces blood viscosity and platelet aggregation (antiplatelet effect). Inhibits the formation of free radicals (antioxidant effect). It has a membrane stabilizing effect. Increases tissue resistance to oxygen deficiency (antihypoxic effect).

Possesses retinoprotective properties, protects the retina and other tissues of the eye from the damaging effects of high intensity light. Promotes resorption of intraocular hemorrhages, reduces blood clotting, improves microcirculation of the eye. Stimulates the reparative processes in the cornea (including in the early postoperative and post-wound period).

Pharmacokinetics

Distribution

It quickly penetrates into organs and tissues, where it is deposited and metabolized. In the tissues of the eye, the concentration is higher than in the blood.

Metabolism

Found 5 metabolites, represented by dealkylated and conjugated conversion products. Metabolites are excreted by the kidneys. 2-ethyl-6-methyl-3-hydroxypyridine phosphate is found in significant quantities in the liver tissue.

Indications of the drug Emoxy-OpticЃ

• hemorrhage in the anterior chamber of the eye (treatment);

• hemorrhages in the sclera in the elderly (treatment and prevention);

• inflammation and burns of the cornea (treatment and prevention);

• complications of myopia (treatment);

• corneal protection (when wearing contact lenses)

  Side effect

  Local reactions: burning sensation, itching, short-term conjunctival hyperemia; rarely - local allergic reactions.

  Contraindications for use

  • pregnancy;

  • lactation period (breastfeeding);

  • children and adolescents up to 18 years old;

  • hypersensitivity to the components of the drug.

  Application during pregnancy and lactation

  The drug is contraindicated during pregnancy and lactation (breastfeeding).

  Application in children

  Contraindication: children and adolescents up to 18 years of age.

  special instructions

  If necessary, the simultaneous use of other eye drops, the drug is instilled last, after complete absorption of the previous drops (not less than 10-15 minutes).

  Overdose

  An overdose of Emoxy-opticЃ has not been established.

  Drug interactions

  Do not mix Emoxy-opticЃ with other drugs.